Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-17-004937
Filing Date
2017-05-11
Accepted
2017-05-11 16:06:26
Documents
81
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0317_immucellcorp.htm 10-Q 606850
2 CERTIFICATION f10q0317ex31_immucellcorp.htm EX-31 9612
3 CERTIFICATION f10q0317ex32_immucellcorp.htm EX-32 5491
  Complete submission text file 0001213900-17-004937.txt   4748421

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE iccc-20170331.xml EX-101.INS 920439
5 XBRL SCHEMA FILE iccc-20170331.xsd EX-101.SCH 49214
6 XBRL CALCULATION FILE iccc-20170331_cal.xml EX-101.CAL 71574
7 XBRL DEFINITION FILE iccc-20170331_def.xml EX-101.DEF 126866
8 XBRL LABEL FILE iccc-20170331_lab.xml EX-101.LAB 487468
9 XBRL PRESENTATION FILE iccc-20170331_pre.xml EX-101.PRE 314527
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12934 | Film No.: 17834292
SIC: 2835 In Vitro & In Vivo Diagnostic Substances